Chronic fatigue syndrome and the XMRV virus

There are many ways to fall prey to simplistic linear thinking when desperately seeking solutions to complex problems. Chronic Fatigue Syndrome can be a devastating illness; as attractive as a viral culprit may be to some, there is abundant evidence that attributing this complex condition to a singular cause unrealistically ignores the complexity of CFS and related conditions. A study just published in the Journal of Virology is the most recent ‘nail in the coffin’ for the notion that CFS is caused by the XMRV virus. The authors state:

Chronic fatigue syndrome (CFS) is a multi-system disorder characterized by prolonged and severe fatigue that is not relieved by rest…Recently CFS has been associated with xenotropic murine leukemia virus-related virus (XMRV) as well as other murine leukemia virus (MLV)-related viruses, though not all studies have found these associations.”

They analyzed blood samples from 100 CFS patients and 200 self-reported healthy volunteers using molecular, serological and viral replication assays. Interestingly, they also analyzed samples from patients in the original study that attracted so much media attention when it reported XMRV in CFS. What were the results?

We did not find XMRV or related MLVs, either as viral sequences or infectious virus, nor did we find antibodies to these viruses in any of the patient samples, including those from the original study. We show that at least some of the discrepancy with previous studies is due to the presence of trace amounts of mouse DNA in the Taq polymerase enzymes used in these previous studies.”

Attention to their conclusion may prevent clinicians and CFS sufferers from a fruitless diversion:

Our findings do not support an association between CFS and MLV-related viruses including XMRV and off-label use of antiretrovirals for the treatment of CFS does not seem justified at present.”

This is a thorough and detailed study, but is there any other evidence to support the assertion that we shouldn’t depend on XMRV as a linear viral cause for CFS? A study recently published in the journal Retrovirology also finds no association in cases across the US:

“Here we tested blood specimens from 45 CFS cases and 42 persons without CFS from over 20 states in the United States for both XMRV and MuLV. The CFS patients all had a minimum of 6 months of post-exertional malaise and a high degree of disability, the same key symptoms described in the Lombardi et al. study. Using highly sensitive and generic DNA and RNA PCR tests, and a new Western blot assay employing purified whole XMRV as antigen, we found no evidence of XMRV or MuLV in all 45 CFS cases and in the 42 persons without CFS. Our findings, together with previous negative reports, do not suggest an association of XMRV or MuLV in the majority of CFS cases.”

Additional research published shortly after in the same journal came up with the same negative results for both CFS and prostate cancer in Japan:

“To evaluate the risk of XMRV infection during blood transfusion in Japan, we screened three populations–healthy donors (n = 500), patients with PC (n = 67), and patients with CFS (n = 100)–for antibodies against XMRV proteins in freshly collected blood samples. We also examined blood samples of viral antibody-positive patients with PC and all (both antibody-positive and antibody-negative) patients with CFS for XMRV DNA.”

Their data led them to the following conclusion:

“Our data show no solid evidence of XMRV infection in any of the three populations tested, implying that there is no association between the onset of PC or CFS and XMRV infection in Japan.”

A study recently published in PLoS ONE (Public Library of Science) goes a step further in examining the issue. The authors state:

“The novel human gammaretrovirus xenotropic murine leukemia virus-related virus (XMRV), originally described in prostate cancer, has also been implicated in chronic fatigue syndrome (CFS). When later reports failed to confirm the link to CFS, they were often criticised for not using the conditions described in the original study. Here, we revisit our patient cohort to investigate the XMRV status in those patients by means of the original PCR protocol which linked the virus to CFS.”

In addition to the PCR protocol used in the original study, the authors also assayed the sera of CFS patients for the presence of both the xenotropic virus envelope protein and a serological response to it. What did their data show?

The results further strengthen our contention that there is no evidence for an association of XMRV with CFS, at least in the UK.”

Subsequent research also conducted in the UK and published in PLoS examined a highly susceptible cohort of patients for XMRV virus:

We extracted peripheral blood DNA from a cohort of 540 HIV-1-positive patients (approximately 20% of whom have never been on anti-retroviral treatment) and determined the presence of XMRV and related viruses using TaqMan PCR.”

Even for this very vulnerable group XMRV was not proven to be a concern:

In view of these negative findings in this highly susceptible group, we conclude that it is unlikely that XMRV or related viruses are circulating at a significant level, if at all, in HIV-1-positive patients in London or in the general population.

The authors of a study just published in the Annals of Neurology go a step further in investigating whether XMRV could be a causative agent in CFS. Having acknowledged the pre-existing research, they state:

“A useful next step would be to examine cerebrospinal fluid, because in some patients CFS is thought to be a brain disorder. Finding a microbe in the central nervous system would have greater significance than in blood because of the integrity of the blood–brain barrier.”

The brain is at the core of the experience of fatigue; if the virus were to show up anywhere it should be there. What did they find?

We examined cerebrospinal fluid from 43 CFS patients using polymerase chain reaction techniques, but did not find XMRV or multiple other common viruses, suggesting that exploration of other causes or pathogenetic mechanisms is warranted.”

Just because a virus may be found in the body of a patient with CFS or any other condition does not mean that it is a significant causal factor for their complaint. The authors of a paper published in the British Medical Bulletin undertook a survey of…

“…All papers including the wording XMRV were abstracted from the NIH library of medicine database and included in the analysis.”

They make the point that…

“An increasing number of papers now refute the association of XMRV with human disease in humans although there is some evidence of serological reactivity to the virus. While it is unlikely that XMRV is a major cause of either prostate cancer or CFS, it can infect human cells and might yet have a role in human disease.”

But there is a big difference between being present in human cells and being a cause of disease. This is illustrated by a fascinating study published in the Journal of Virology showing that XMRV does not efficiently replicate and spread in human tissue. The authors state:

“To determine whether XMRV can replicate and spread in cultured PBMCs even though it can be inhibited by A3G/A3F, we infected phytohemagglutinin-activated human PBMCs and A3G/A3F-positive and -negative cell lines (CEM and CEM-SS, respectively) with different amounts of XMRV and monitored virus production by using quantitative real-time PCR.”

They summarize their findings by concluding:

“We found that XMRV efficiently replicated in CEM-SS cells and viral production increased by >4,000-fold, but there was only a modest increase in viral production from CEM cells (<14-fold) and a decrease in activated PBMCs, indicating little or no replication and spread of XMRV…Overall, these results suggest that hypermutation of XMRV in human PBMCs constitutes one of the blocks to replication and spread of XMRV.”

Wishing for a single linear cause that will lend itself to the discovery of a ‘magic bullet’ for conditions that are engendered by a multi-causal systemic web of factors is a flaw that has hindered progress in the treatment of chronic disease. In the case of CFS, dysregulation of the brain-immune axis is a core component. This demands that the clinician integrate a panoramic systems view with a nuanced investigation of individual functional elements. There is a world of science to delve into here; research just published in the journal NMR In Biomedicine offers a taste of the brain aspect. The authors in order to:

“…explore brain involvement in chronic fatigue syndrome (CFS), the statistical parametric mapping of brain MR [magnetic resonance] images has been extended to voxel-based regressions against clinical scores.”

The compared MR signal levels in 25 CFS subjects and 25 normal controls, including such clinical scores as fatigue duration, another score based on the 10 most common CFS symptoms, the hospital anxiety and depression scale (HADS) anxiety and depression, and hemodynamic parameters from 24 hour blood pressure monitoring. What did their data show?

“In the midbrain, white matter volume was observed to decrease with increasing fatigue duration. For T1-weighted MR and white matter volume, group × hemodynamic score interactions were detected in the brainstem [strongest in midbrain grey matter (GM)], deep prefrontal white matter (WM), the caudal basal pons and hypothalamus. A strong correlation in CFS between brainstem GM volume and pulse pressure suggested impaired cerebrovascular autoregulation. It can be argued that at least some of these changes could arise from astrocyte dysfunction.”

In other words, there were strong correlations between CFS symptoms and pathological changes in the brain. The authors conclude:

“These results are consistent with an insult to the midbrain at fatigue onset that affects multiple feedback control loops to suppress cerebral motor and cognitive activity and disrupt local CNS homeostasis, including resetting of some elements of the autonomic nervous system (ANS).

How might such neurodegenerative changes come about? A paper published earlier in Autoimmunity Reviews discusses the autoimmune component of CFS:

“The current concept is that CFS pathogenesis is a multifactorial condition. Various studies have sought evidence for a disturbance in immunity in people with CFS. An alteration in cytokine profile, a decreased function of natural killer (NK) cells, a presence of autoantibodies and a reduced responses of T cells to mitogens and other specific antigens have been reported. The observed high level of pro-inflammatory cytokines may explain some of the manifestations such as fatigue and flu-like symptoms and influence NK activity. Abnormal activation of the T lymphocyte subsets and a decrease in antibody-dependent cell-mediated cytotoxicity have been described. An increased number of CD8+ cytotoxic T lymphocytes and CD38 and HLA-DR activation markers have been reported, and a decrease in CD11b expression associated with an increased expression of CD28+ T subsets has been observed.”

The main point: practitioners and patients should not be seduced by the wish for a ‘magic bullet’ treatment of a single linear cause for complex conditions that require a systems biology perspective. In the case of chronic fatigue syndrome, the brain-immune axis comes to the fore, with all its multifaceted considerations for functional assessment and treatment.

Canker sores and autoimmune thyroiditis

It may not be recognized widely enough that recurrent canker sores (aphthous stomatitis) is an autoimmune disorder. A study just published in the Journal of the European Academy of Dermatology and Venereology investigates the association between recurrent canker sores and autoimmune thyroid disease (the most common cause of low thyroid function in developed countries). The authors state:

Recurrent aphthous stomatitis (RAS) is an autoimmune disorder characterized by the periodic appearance of aphthous lesions on the oral mucosa. TH1 cytokines plays a key role in the aetiopathogenesis. Autoimmune thyroid disease (ATD) is the most common autoimmune disease and is frequently accompanied by various other autoimmune diseases.”

They examined ninety patients and 30 healthy volunteers by measuring thyroid stimulant hormone (TSH), free and total triiodothyronin (fT3, TT3), free and total thyroxin (fT4, TT4), thyroglobulin, and the most common antibodies found in autoimmune thyroiditis, anti-thyroid peroxidase antibody (anti-TPO) and anti-thyroglobulin antibody (anti-TG. They also performed thyroid ultrasonography. Their data showed a connection:

“The anti-thyroid antibody was positive in 31.11% of the patients with RAS, and in only 10% of the individuals in the control group. The mean anti-TG level was also higher in the RAS group. Ultrasonography revealed nodules in 28.8% of the patients with RAS and in 16.7% of the individuals in the control group. The sT4 levels were lower and the TSH, anti-TPO and anti-TG levels were significantly higher in the RAS patients with thyroid nodules than the RAS patients without nodules.”

Rarely is there only one tissue target in an autoimmune state. Personally, I feel that an important question for any practitioner confronting a condition characterized by chronic inflammation is: “to what degree is there an autoimmune component?” The authors conclude:

The frequency of thyroid autoimmune-related problems was higher in patients with RAS. It would be worthy of searching autoimmune thyroid disorders in patients with RAS.”

Cytokines with autoimmune hepatitis

Those interested in the management of autoimmune hepatitis as a condition in itself or as a complication of infectious hepatitis will appreciate a study just published in the journal Hepatology Research.

“This study investigated the relationship between circulating cytokines in the pretreatment phase and remission following corticosteroid therapy phase in Japanese AIH [autoimmune hepatitis] patients.”

The authors measured 28 cytokines by multiple bead array technology in 40 patients with AIH during pretreatment and remission phases. A particular pattern stood out:

Interleukin (IL)-12p40, interferon-γ-inducible protein (IP-10), macrophage inflammatory protein (MIP)-1α, MIP-1β, IL-17F and IL-18 were significantly decreased during remission from pretreatment stage levels. The level of IP-10 in the pretreatment phase was correlated with serum levels of alanine aminotransferase.”

An assay of these cytokines can help to answer two important questions: (1) does this patient have an autoimmune component to their hepatitis, and (2) are they responding to treatment? The authors’ conclusion is worth bearing in mind when these kinds of cases come up:

“Our results suggest that a complex interplay of several cytokines, especially pro-inflammatory and T-helper 17 cytokines and regulatory T-cell suppression by IL-12p40 may play a pivotal role in the pathogenesis of AIH.”

Persistent gastrointestinal symptoms demand a look at the brain-gut axis

Assuming that gross pathologies, infections and dietary imprudence have been ruled out, persistent gastrointestinal symptoms require an assessment of the brain-gut axis. More than ever before, research is revealing the profound degree to which gastrointestinal function and even tissue integrity depend on brain output. A spate of earlier reports emphasized the abnormal brain response to sensory signals received from the gut, as in a paper published in Gastroenterology Clinics of North America. The author states:

“Functional neuroimaging studies have demonstrated evidence of altered regional brain activation responses during visceral and somatic stimuli in IBS [irritable bowel syndrome]…Altered brain responses in IBS, particularly to visceral stimuli, include activation of regions concerned with attentional processes and response selection, corticolimbic regions concerned with emotional and autonomic responses to stimuli, and subcortical regions receiving cortical projections from the latter and afferent input from the soma [body] and viscera [organs].”

And remarkably…

Altered activations of these regions also may be present [even] in the absence of a noxious visceral stimulus.

A further indication of the relevance of these observations is that…

“Changes in rCBF [regional cerebral blood flow, a metric for brain function] of some of these regions have been associated with treatment response in IBS.”

As in so many other clinical conditions, loss of cortical inhibitory function—the brain’s great task of calming or attenuating incoming signals—is suggested here:

“A plausible hypothesis for the observations from brain imaging studies is that IBS patients demonstrate a compromised activation of pain inhibition circuits including those of the cortico-pontine circuit but increased activation of limbic and paralimbic circuits that may be related to pain facilitation.”

The authors of a study published in the American Journal of Gastroenterology come to a similar conclusion. Importantly, they also note an association with fibromyalgia:

“Symptoms of irritable bowel syndrome (IBS) and fibromyalgia (FM) commonly coexist. We hypothesized that one of the mechanisms underlying this comorbidity is increased activation of brain regions concerned with the processing and modulation of visceral and somatic afferent information, in particular subregions of the anterior cingulate cortex (ACC).”

With their data they were able to discriminate between IBS and IBS + fibromyalgia in the modulation of brain responses to stimuli:

“”Whereas the somatic stimulus was less unpleasant than the visceral stimulus for IBS patients without FM, the somatic and visceral stimuli were equally unpleasant in the IBS + FM group…There was a greater rCBF increase in response to noxious visceral stimuli in IBS patients and to somatic stimuli in IBS + FM patients.”

Thus the authors conclude that exaggerated brain responses to peripheral stimuli play a role in both IBS and FM. In this context ‘cognitive enhancement’ means inhibition failure:

Chronic stimulus-specific enhancement of ACC responses to sensory stimuli in both syndromes may be associated with cognitive enhancement of either visceral (IBS) or somatic (IBS + FM) sensory input and may play a key pathophysiologic role in these chronic pain syndromes.”

Brain control of the immune system in the gut and disturbances in neuroimmune regulation that persist long after an initial insult such as GI infection are discussed in a paper just published in Nature Reviews Gastroenterology & Hepatology. The authors state:

IBS is one of the most common functional gastrointestinal disorders worldwide and is thought to be the result of disturbed neural function along the brain–gut axis…important roles for low-grade inflammation and immunological alterations in the development of symptoms compatible with IBS have become evident.”

As in so many other varied conditions and chronic pain syndromes, disturbance of the regulatory loop between the brain and periphery becomes the cause of chronic symptoms even long after the initial insult has resolved:

“The development of long-standing gastrointestinal symptoms after infectious gastroenteritis and patients with IBD [inflammatory bowel disease] in remission frequently having functional gastrointestinal symptoms support this hypothesis.”

Loss of the barrier function of the lining of the intestine that separates its contents from the surrounding immune tissue—abnormal intestinal permeability—is a key feature of brain-gut neuroimmune dysfunction.

“In addition, studies have demonstrated that IBS may be associated with an activated adaptive immune response. Increased epithelial barrier permeability and an abnormal gut flora might lead to increased activation of the intestinal immune system. Functional and anatomical evidence for abnormal neuroimmune interactions has been found in patients with IBS.

Clinicians and patients alike with experience of complaints associated with intestinal permeability appreciate how vexing a problem this can be to manage. A fascinating paper published in the Journal of Neurotrauma sheds light on the usually overlooked yet critical role of the brain in maintaining and repairing the gut lining. The authors state:

Traumatic brain injury (TBI) can lead to several physiologic complications including gastrointestinal dysfunction. Specifically, TBI can induce an increase in intestinal permeability, which may lead to bacterial translocation, sepsis, and eventually multi-system organ failure.”

They examined animals subject to TBI for expression of the zonulin [ZO-1] and occludin, proteins critical for integrity of the intestinal lining, to determine if they decreased following TBI. They also looked for a subsequent increase in intestinal permeability. What did their data show?

TBI caused a significant increase in intestinal permeability compared to sham animals 6 h after injury. Expression of ZO-1 was decreased by 49% relative to sham animals, whereas expression of occludin was decreased by 73% relative to sham animals.”

This has great clinical significance: brain output is critical for maintenance of the intestinal epithelium. The authors conclude:

An increase in intestinal permeability corresponds with decreased expression of tight junction proteins ZO-1 and occludin following TBI. Expression of intestinal tight junction proteins may be an important factor in gastrointestinal dysfunction following brain injury.”

A paper published in the Journal of Physiology and Pharmacology describes one effect of disturbance of the brain-gut axis as an increase in visceral sensitivity. The authors note:

“Chronic abdominal pain is the most distressing symptom in patients with functional digestive disorders (FDD)…a chronic visceral hyperalgesia, in the absence of detectable organic disease, is implicated…Several lines of evidence suggest a strong modulatory or etiologic role of the central nervous system in the pathophysiology of IBS…These findings were consistent with an IBS model that includes both the exaggerated activation of a vigilance network (dorsolateral PFC) and a failure in pain inhibition network anterior cingulate cortex (ACC).”

They report their findings on using fMRI (functional magnetic resonance imaging) to characterize the areas of the brain activated by rectal distension in healthy volunteers and compared them with the activation patterns in a population of IBS patients. In the latter…

“…we did not observe any neuronal activation in locations activated in healthy volunteers (ACC [anterior cingulate cortex], dorsolateral PFC) while a significant deactivation was observed in the IC [insular cortex] and in the amygdala, a limbic structure with a role to assign emotional significance to a current experience related to anxiety and fear. Brain imaging techniques thus appear as useful tools to characterize normal and abnormal brain processing of visceral pain in patients with FDD.”

Another study published recently in the same journal reported on the brain’s output for stimulating the production of pancreatic digestive enzymes:

Brain is also implicated in the regulation of pancreatic exocrine function. Dorsal vagal complex of the brainstem (DVC) appears the center of long vago-vagal cholinergic entero-pancreatic reflex.”

It is of great practical importance for clinicians to bear in mind that the immune system is part of the brain-gut axis, and that there is a bi-directional communication between the enteric nervous and immune systems in the gut and the brain. Naturally brain-gut regulation is also influenced by emotion and cognition. A review just published in the journal Brain, Behavior and Immunity offers an aerial perspective:

“The role of central nervous system mechanisms along the “brain-gut axis” is increasingly appreciated, owing to accumulating evidence from brain imaging studies that neural processing of visceral stimuli is altered in IBS together with long-standing knowledge regarding the contribution of stress and negative emotions to symptom frequency and severity.”

Regarding the role of the immune system:

“At the same time, there is also growing evidence suggesting that peripheral immune mechanisms and disturbed neuro-immune communication could play a role in the pathophysiology of visceral hyperalgesia.”

The authors also assert that the higher level of “top-down” regulation must be considered:

“…recent advances in research on the pathophysiology of visceral hyperalgesia…support that in addition to lower pain thresholds displayed by a significant proportion of patients, the evaluation of pain appears to be altered…Disturbed “top-down” emotional and cognitive pain modulation in IBS is reflected by functional and possibly structural brain changes involving prefrontal as well as cingulate regions.”

And, of course, it’s a ‘two-way street’—disturbed immune and neural signalling go the other way too:

“At the same time, there is growing evidence linking peripheral and mucosal immune changes and abdominal pain in IBS, supporting disturbed peripheral pain signalling. Findings in post-infectious IBS emphasize the interaction between centrally-mediated psychosocial risk factors and local inflammation in predicting long-term IBS symptoms.”

The authors of a paper published in Gastroentérologie Clinique et Biologique also comment on this two-way channel:

There is a bidirectional relation between the central nervous system and the digestive tract, i.e., the brain-gut axis. Numerous data argue for a dysfunction of the brain-gut axis in the pathophysiology of irritable bowel syndrome (IBS). Visceral hypersensitivity is a marker of IBS as well as of an abnormality of the brain-gut axis. This visceral hypersensitivity is peripheral and/or central in origin and may be the consequence of digestive inflammation or an anomaly of the nociceptive [pain-sensing] message treatment at the spinal and/or supraspinal level.”

Importantly, brain-gut axis dysregulation is also expressed through the autonomic (sympathetic and parasympathetic) nervous system…

Disturbances of the autonomic nervous system are observed in IBS as a consequence of brain-gut axis dysfunction.”

A study published in the journal Neurology offers additional evidence that the brain is a key component of chronic gastrointestinal and other chronic pain disorders . The authors recognize the link between this and fibromyalgia:

“Abnormal cortical pain responses in patients with fibromyalgia and conversion disorder raise the possibility of a neurobiologic basis underlying so-called “functional” chronic pain.”

They used fMRI (functional MRI) to examine the brains of healthy subjects and those with IBS while stimulating with rectal distension. Their experiences with pain or urging were correlated with the fMRI data. There was a clear difference between the IBS and normal subjects:

“In IBS, abnormal responses associated with rectal-evoked sensations were identified in five brain regions. In primary sensory cortex, there were urge-related responses in the IBS but not control group. In the medial thalamus and hippocampus, there were pain-related responses in the IBS but not control group.”

The authors concluded:

“Percept-related fMRI revealed abnormal urge- and pain-related forebrain activity during rectal distension in patients with irritable bowel syndrome (IBS)…abnormal brain responses in IBS may reflect the sensory symptoms of rectal pain and hypersensitivity, visceromotor dysfunction, and abnormal interoceptive processing.”

The authors of another paper published in Gastroentérologie Clinique et Biologique came to similar conclusions regarding the interactions of the brain, immune system and higher functions. [For lay readers of this post: the enteric nervous system (the 'brain in the gut') is part of the autonomic nervous system that regulates all visceral functions including those in the gut].

“Hypersensitivity is due either to an afferent neurons dysfunction at the enteric nervous system level, either to an abnormal brain-gut axis processing of sensory or nociceptive inputs arising from the gut, at the spinal or supraspinal level. Disturbances of the autonomic nervous system occur in IBS as a consequence of this brain-gut axis dysfunction.”

Moreover…

“Neurological abnormalities may be triggered by inflammation, mast cell [a type of immune cell] dysfunction or increased intestinal permeability while the neuro-immune consequences of stress (mainly chronic) play a major role…”

And of course…

“The role of emotions and mood disturbances cannot be omitted in the interpretation the central processing of digestive sensory inputs. Neurosciences, in particular brain imaging techniques, have contributed to this better understanding of irritable bowel syndrome pathophysiology.”

A study published in The Journal of Neuroscience demonstrates how anticipation can affect brain regions that function to regulate sensory signals coming from the gut:

“Cognitive factors such as fear of pain and symptom-related anxiety play an important role in chronic pain states. The current study sought to characterize abnormalities in preparatory brain response before aversive pelvic visceral distention in irritable bowel syndrome (IBS) patients and their possible relationship to the consequences of distention.”

They too used brain fMRI to examine the differences in response to rectal distention between IBS patients and healthy controls. Their data showed marked differences in the ability to activate brain areas responsible for anticipatory calming and for inhibition of sensory signals coming from the intestines during distention:

“During cued anticipation of distention, activity decreased in the insula, supragenual anterior cingulate cortex (sACC), amygdala, and dorsal brainstem (DBS) of controls. IBS patients showed less anticipatory inactivation…During subsequent distention, both groups showed activity increases…[relevant brain areas]…The increases were more extensive in patients, producing significant group differences in dorsal ACC and DBS.”

The authors conclude that diminished inhibitory function may result in a heightened sensitivity to sensations from the gut:

“Deficits in preparatory inhibition of DBS, including the locus ceruleus complex and parabrachial nuclei, may interfere with descending corticolimbic inhibition and contribute to enhanced brain responsiveness and perceptual sensitivity to visceral stimuli in IBS.”

A subsequent study published in the journal GUT, An International Journal of Gastroenterology and Hepatology specifically examines the effect of anxiety and depression on the central nervous system processing of visceral stimuli. The authors set out to…

“…address the role of anxiety and depression symptoms in altered pain processing in irritable bowel syndrome (IBS).

They too used fMRI to compare patients with IBS to normal controls for the experience of pain or discomfort in correlation with brain activation. As before the data told an unambiguous story:

“Anxiety symptoms in IBS were significantly associated with pain-induced activation of the anterior midcingulate cortex and pregenual anterior cingulate cortex. Depression scores correlated with activation of the prefrontal cortex (PFC) and cerebellar areas within IBS. Group comparisons with the two-sample t test revealed significant activation in the IBS versus controls contrast in the anterior insular cortex and PFC.”

This is certainly not earth-shaking news, but it does objectively show how anxiety and depression can affect brain function in such a way that visceral stimuli are permitted to bombard the senses abnormally:

Altered central processing of visceral stimuli in IBS is at least in part mediated by symptoms of anxiety and depression, which may modulate the affective–motivational aspects of the pain response.

The authors of a review published in Psychopharmacology document how the stress of maternal separation can cause brain-gut axis dysfunction. Referring to early life stress they state…

“…stress during this critical period also induces alterations in many systems throughout the body…Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that is thought to involve a dysfunctional interaction between the brain and the gut. Essential aspects of the brain–gut axis include spinal pathways, the hypothalamic pituitary adrenal axis, the immune system, as well as the enteric microbiota. Accumulating evidence suggest that stress, especially in early life, is a predisposing factor to IBS.”

Having reviewed the relevant data, they…

“…describe the components of the brain–gut axis individually and how they are altered by maternal separation. The separated phenotype is characterised by alterations of the intestinal barrier function, altered balance in enteric microflora, exaggerated stress response and visceral hypersensitivity…”

What are practitioners to make of all this when endeavoring to help someone with a chronic gastrointestinal complaint? Having investigated for gross pathologies, infections, and food allergies or intolerances, the science indicates that we must accept the role of the brain-gut axis in enteric immune function, maintaining the gut epithelium, and regulating digestive function and sensory phenomena. The brain-gut axis, like all sentient biological entities, is an emergent system. A quote from David Brooks writing in the New York Times offers a working definition:

Emergent systems are ones in which many different elements interact. The pattern of interaction then produces a new element that is greater than the sum of the parts, which then exercises a top-down influence on the constituent elements…Emergent systems are bottom-up and top-down simultaneously. They have to be studied differently, as wholes and as nested networks of relationships.”

Realistically, case management of brain-gut axis disorders requires attending to the multiple factors that influence brain function (a brief overview is available as the Parents’ Guide To Brain Health; it pertains equally to adults). Bottom-up and top-down simultaneously in this case implies that the physiological capacity of the brain to inhibit and stimulate appropriately, and cognition/emotion, are given equal treatment with the condition of the gut microbial ecology and factors that may promote a local inflammatory response. A full treatment of this topic is at least a weighty volume, but there are some recent reports of practical clinical significance on centrally acting therapies for the brain-gut axis worth mentioning in this context. The authors of a paper published in Gastroenterology Clinics of North America state:

“Irritable bowel syndrome (IBS) and other functional gastrointestinal (GI) disorders typically defy traditional diagnostic methods based on structural abnormalities, and has led to the emergence of the discipline of neurogastroenterology or the study of the “brain-gut axis,” which is based on dysregulation of neuroenteric pathways as a key pathophysiological feature of IBS. Centrally acting treatments can influence these pathways and improve the clinical manifestations of pain and bowel dysfunction associated with this disorder. To successfully implement these treatment strategies, it is important to recognize their dual effects on brain and gut…

In this respect we can appreciate the key role of the autonomic nervous system since there are practical ways to objectively evaluate ANS function in an office-based practice (heart rate variability analysis) and non-invasive therapies that modulate the brain and ANS through sensory-based peripheral modalities (all kinds of peripheral stimuli applied to elicit a corrective central response). The author of a paper published recently in La revue de médecine interne notes:

“Our digestive tract has an autonomous functioning but also has a bidirectional relation with our brain known as brain-gut interactions. This communication is mediated by the autonomous nervous system, i.e., the sympathetic and parasympathetic nervous systems, with a mixed afferent and efferent component, and the circumventricular organs located outside the blood-brain barrier. The vagus nerve, known as the principal component of the parasympathetic nervous system…has also anti-inflammatory properties both through the hypothalamic pituitary adrenal axis (through its afferents) and the cholinergic anti-inflammatory pathway (through its efferents). The sympathetic nervous system has a classical antagonist effect on the parasympathetic nervous system at the origin of an equilibrated sympathovagal balance in normal conditions.”

This invites another look at an earlier post documenting the anti-inflammatory role of the parasympathetic nervous system and the use of heart rate variability analysis to objectively evaluate its function. The ANS is the neural communicating channel between the brain and the gut, offering therapeutic access to both…

“The brain is able to integrate inputs coming from the digestive tract inside a central autonomic network organized around the hypothalamus, limbic system and cerebral cortex (insula, prefrontal, cingulate) and in return to modify the autonomic nervous system and the hypothalamic pituitary adrenal axis in the frame of physiological loops. A dysfunction of these brain-gut interactions, favoured by stress, is most likely involved in the pathophysiology of digestive diseases such as irritable bowel syndrome or even inflammatory bowel diseases. A better knowledge of these brain-gut interactions has therapeutic implications in the domain of pharmacology, neurophysiology, behavioural and cognitive management.”

This gives us background to appreciate a fascinating study published recently in The Journal of Trauma—Injury Infection & Critical Care offering evidence that ANS, specifically vagal, stimulation can prevent the loss of intestinal barrier function associated with traumatic brain injury. The authors state:

“Traumatic brain injury (TBI) causes gastrointestinal dysfunction and increased intestinal permeability. Regulation of the gut barrier may involve the central nervous system. We hypothesize that vagal nerve stimulation prevents an increase in intestinal permeability after TBI.”

They subjected their study animals to TBI after a selected cohort had undergone electrical stimulation of the cervical vagus nerve. They subsequently measured intestinal permeability, tumor necrosis factor-α (an inflammatory cytokine) and, very interestingly, glial fibrillary acidic protein (GFAP) which is a marker of enteric glial activity. What did they find?

“TBI increased intestinal permeability compared with sham…Vagal stimulation prevented TBI-induced intestinal permeability. TBI animals had an increase in intestinal tumor necrosis factor-α 6 hours after injury compared with vagal stimulation + TB…intestinal GFAP was 18.0-fold higher at 4 hours compared with sham and 1.6-fold higher than TBI alone.”

This has profound and practical clinical implications:

“In a mouse model of TBI, vagal stimulation prevented TBI-induced intestinal permeability. Furthermore, vagal stimulation increased enteric glial activity and may represent the pathway for central nervous system regulation of intestinal permeability.”

A paper published last summer in the Journal of Neurogastroenterology and Motility offers one example of a sensory-based peripheral modality that has a therapeutic effect on these central processes, in this case electroacupuncture.

“We evaluated the effect of acupuncture in treating visceral hyperalgesia in an animal model.”

The authors applied either electroacupuncture (EA) or sham acupuncture at acupoint ST-36 to rats with prior neonatal maternal separation stress. The day after the acupuncture treatment they were subject to colorectal distension, comparing them for pain threshold and visceromotor response. They also measured serotonin and Fos expression by immunohistochemistry in the colon, brainstem and spinal cord.

“Rats in EA group had significantly higher pain threshold compared to those in sham acupuncture group…They also had lower visceromotor response as measured by electromyogram compared to those received sham acupuncture at all colorectal distension pressures.”

Electroacupuncture is one of a number of ways to simulate the brain through sensory pathways. In this study the authors concluded:

“Electro acupuncture attenuates visceral hyperlagesia through down-regulation of central serotonergic activities in the brain-gut axis.”

My heart goes out to these study animals, but we can accept the further evidence presented in another paper published recently in The Journal of Trauma—Injury Infection & Critical Care. In this study the authors demonstrated repair of the gut barrier through vagal stimulation after abnormal intestinal permeability induced by burn trauma:

“Severe injury can cause intestinal permeability through decreased expression of tight junction proteins, resulting in systemic inflammation. Activation of the parasympathetic nervous system after shock through vagal nerve stimulation is known to have potent anti-inflammatory effects…We postulated that vagal nerve stimulation improves intestinal barrier integrity after severe burn through an efferent signaling pathway, and is associated with improved expression and localization of the intestinal tight junction protein occludin.”

The authors subjected their animals to burn injury after vagal nerve stimulation for 10 minutes. A separate underwent abdominal vagotomy before vagal nerve stimulation and burn. Intestinal barrier injury, histology, and changes in occludin expression were then assessed. The results were striking…

“Cervical vagal nerve stimulation decreased burn-induced intestinal permeability to FITC-dextran, returning intestinal permeability to sham levels. Vagal nerve stimulation before burn also improved gut histology and prevented burn-induced changes in occludin protein expression and localization. Abdominal vagotomy abrogated the protective effects of cervical vagal nerve stimulation before burn, resulting in gut permeability, histology, and occludin protein expression similar to burn alone.”

Improving parasympathetic function in general and vagal function in particular is of paramount importance in the management of most chronic disorders. The authors conclude:

Vagal nerve stimulation performed before injury improves intestinal barrier integrity after severe burn through an efferent signaling pathway and is associated with improved tight junction protein expression.

Actual case management of brain-gut axis disorders merits an entire textbook, but this can be borne in mind: diet, supplements, medicines, etc. are not enough—good gut function requires good brain output and autonomic regulation. Clinicians actively treating these conditions who are interested in how we apply functional testing for GI inflammation, infection, gut permeability, allergy, ANS function, the brain and brain-gut axis, etc.; and the various therapies brought to bear on the findings; are welcome to contact Lapis Light for collegial conversation.

 

IBS aetiology is most likely multi-factorial involving biological, psychological and social factors. Visceral hyperalgesia (or hypersensitivity) and visceral hypervigilance, which could be mediated by peripheral, spinal, and/or central pathways, constitute key concepts in current research on pathophysiological mechanisms of visceral hyperalgesia. The role of central nervous system mechanisms along the “brain-gut axis” is increasingly appreciated, owing to accumulating evidence from brain imaging studies that neural processing of visceral stimuli is altered in IBS together with long-standing knowledge regarding the contribution of stress and negative emotions to symptom frequency and severity. At the same time, there is also growing evidence suggesting that peripheral immune mechanisms and disturbed neuro-immune communication could play a role in the pathophysiology of visceral hyperalgesia. This review presents recent advances in research on the pathophysiology of visceral hyperalgesia in IBS, with a focus on the role of stress and anxiety in central and peripheral response to visceral pain stimuli. Together, these findings support that in addition to lower pain thresholds displayed by a significant proportion of patients, the evaluation of pain appears to be altered in IBS. This may be attributable to affective disturbances, negative emotions in anticipation of or during visceral stimulation, and altered pain-related expectations and learning processes. Disturbed “top-down” emotional and cognitive pain modulation in IBS is reflected by functional and possibly structural brain changes involving prefrontal as well as cingulate regions. At the same time, there is growing evidence linking peripheral and mucosal immune changes and abdominal pain in IBS, supporting disturbed peripheral pain signalling. Findings in post-infectious IBS emphasize the interaction between centrally-mediated psychosocial risk factors and local inflammation in predicting long-term IBS symptoms. Investigating afferent immune-to-brain communication in visceral hyperalgesia as a component of the sickness response constitutes a promising future research goal.

Radiation protection and iodine supplementation

Ionizing radiation damages DNA and other proteins directly, but does most of its dirty work through oxidative damage when a storm of free radicals are generated by the effect of radiation on water molecules inside the cells. That makes the best protection from ionizing radiation a comprehensive approach that optimizes intrinsic resources for ameliorating oxidative and mutagenic damage. Additionally, it is well known that iodine (potassium iodide) can help to protect the thyroid gland by displacing radioactive forms of the element, but should it be taken preventively? In fact, there is a substantial amount of scientific evidence that great care must be taken when recommending iodine for any health concern. Most clinicians that practice according the functional model are aware that the widespread surge in autoimmune disease presents a specific risk because iodine supplementation can trigger latent or aggravate pre-existing autoimmune thyroiditis (Hashimoto’s disease), as illustrated by a paper published recently in the journal Hormones. The authors state:

“Epidemiological studies have linked increased iodide intake from dietary or other sources to the development of hypothyroidism, and it appears that in several—though not all—cases, this phenomenon has an autoimmune basis.”

They further note:

“Within an immunological context, iodine may mediate thyroiditis induction via at least two mechanisms: a) by increased post-translational modification of thyroglobulin (Tg), an event which may enhance the immunopathogenicity of this molecule as detailed further in this review; and b) via apoptotic/necrotic effects of thyrocytes, a step that could initiate presentation of thyroid antigens at immunostimulatory levels.”

All clinicians who manage conditions for which supplemental iodine therapy is contemplated should bear in mind the authors’ conclusion:

High dietary iodide intake may lead to the development of thyroid autoimmunity via at least two pathways. First, iodide may epigenetically modify the Tg molecule and create iodinated neoantigenic determinants to which immune tolerance has not been established or alter the processing of Tg to facilitate generation of pathogenic but cryptic Tg determinants that may not contain iodine. Second, iodine may precipitate apoptotic/necrotic effects on thyrocytes, thus releasing increased amounts of thyroid antigens that can activate autoreactive T cells in situ or in thyroid-draining lymph nodes. The genetic background of the host may be permissive to one or both of these pathways that may act in synergy or independently of each other.”

The authors of a study published in the Journal of Clinical Endocrinology & Metabolism also weigh in on the subject of hypothyroid due to thyroiditis from high iodine intake:

“Twenty-two patients with spontaneously occurring primary hypothyroidism were studied to evaluate the spontaneous reversibility of the hypothyroid state. Twelve (54.5%) became euthyroid [normal thyroid] after restriction of iodine intake for 3 weeks (reversible type).”

Of particular interest is the finding that:

“Seven patients with the reversible type were given 25 mg iodine daily for 2–4 weeks; all became hypothyroid again...The patients with reversible hypothyroidism had focal lymphocytic thyroiditis changes in the thyroid biopsy specimen, whereas those with irreversible hypothyroidism had more severe destruction of the thyroid gland.”

Their conclusion is consonant with those of the previously mentioned study, and implies that milder forms of thyroiditis may recover if iodine is discontinued:

“These results indicate the existence of a reversible type of hypothyroidism sensitive to iodine restriction and characterized by relatively minor changes in lymphocytic thyroiditis histologically. Attention should be directed to this type of hypothyroidism, because thyroid function may revert to normal with iodine restriction alone.”

Another study published in the journal Biological Trace Element Research finds more evidence for the role of iodine in promoting hypothyroidism. The authors first state:

Excessive iodine intake is known to induce hypothyroidism in people who have underlying thyroid disorders. However, few studies have been performed on subjects with normal thyroid function without a history of autoimmune thyroid disease. We hypothesized that high iodine intake may cause a subtle change in thyroid function even in subjects with normal thyroid function.

They examined 337 subjects with normal levels of thyroid antibodies for urinary iodine excretion, free T4 (FT4), and thyroid-stimulating hormone (TSH).

“The results showed urinary iodine excretion had negative correlation with FT4 and showed a positive trend with TSH. We found that 61.7% of subjects had circulating TPO-Ab within normal reference range. In all subjects, TPO-Ab levels were negatively correlated with FT4 and positively with TSH.”

In other words, as iodine went up the thyroid hormone free T4 went down and TSH (thyroid stimulating hormone)—bother markers for hypothyroid disease. Additionally, while 38.3% had high levels of thyroid peroxidase antibody (proof of autoimmune thyroiditis), for everyone higher levels of TPO-Ab correlated with lower free T4 and higher TSH. (Personally, I have observed that the standard reference ranges for thyroid antibodies are too ‘generous’.) They authors summarize the implications of their data:

“In conclusion, high iodine intake can negatively affect thyroid hormone levels in subjects with normal thyroid function.”

I have heard the Japanese consumption of seaweed cited as evidence for allowing higher levels of iodine intake, but a study published in the Endocrine Journal (of the Japanese Endocrine Society) contradicts this assumption.

“The effect of ingesting seaweed “Kombu” (Laminaria japonica) on thyroid function was studied in normal Japanese adults. Ingesting 15 and 30 g of Kombu (iodine contents: 35 and 70 mg) daily for a short term (7-10 days) significantly increased serum thyrotropin (TSH) concentrations, exceeding the normal limits in some subjectsDuring long term daily ingestion of 15 g of Kombu (55-87 days), the TSH levels were elevated and sustained while the FT4 and FT3 levels were almost unchanged. Urinary excretion of iodine significantly increased during ingestion of Kombu. These abnormal values returned to the initial levels 7 to 40 days after discontinuing the ingestion of Kombu.”

In other words, a diet  heavy on the seaweed Kombu can introduce enough iodine to suppress thyroid function. The authors conclude by recommending:

Based on these findings that thyroid function was suppressed during ingestion of Kombu, though the effect was reversible, we recommend Japanese people avoid ingesting excessive amounts of seaweed.”

Their findings are echoed in a paper published recently in The Medical Journal of Australia which reports…

“…a series of cases of thyroid dysfunction in adults associated with ingestion of a brand of soy milk manufactured with kombu (seaweed), and a case of hypothyroidism in a neonate whose mother had been drinking this milk. We also report two cases of neonatal hypothyroidism linked to maternal ingestion of seaweed made into soup. These products were found to contain high levels of iodine.”

Happily, in both cases the TSH returned and the patients recovered after discontinuing the seaweed enriched soy milk. The conclude with this alert:

Despite increasing awareness of iodine deficiency, the potential for iodine toxicity, particularly from sources such as seaweed, is less well recognised.

Another paper just published in the Journal of Paediatrics and Child Health reports a similar phenomenon and offers a balanced conclusion:

“Mild iodine deficiency is a recognised problem in Australia and New Zealand. However, iodine excess can cause hypothyroidism in some infants. We highlight two cases which illustrate the risks of excess dietary iodine intake during pregnancy and breastfeeding. They also describe a cultural practice of consuming seaweed soup to promote breast milk supply. Although most attention recently has been on the inadequacy of iodine in Australian diets, the reverse situation should not be overlooked. Neither feast nor famine is desirable.

Caution should be used even when applying topical iodine as an antiseptic as reported in a paper published in the journal Anales española de pediatría. They note that iodine-containing antiseptics are still common in obstetrics and neonatology, and that…

“Topical iodine given both to the mother before delivery and to the neonate causes iodine overload. The absorption of maternal iodine through the skin is so fast that iodine in the blood of the umbilical cord increases by 50% a few minutes before delivery. Iodine overload also occurs in the mother. Urinary and breast-milk iodine are increased more than 10-fold in the days after delivery if providone-iodine is used in episiotomy. The overload in the neonate is even higher if breast-fed….this overload can produce thyroid blockade…”

The effects of thyroid blockade in the infant are potentially very serious, especially considering the importance of thyroid function for brain development. The authors conclude with a warning:

Attention should be drawn to the undesirable effects of iodine antiseptics and their use in the perinatal period should be avoided.

Of course there is a place for iodine supplementation in cases of deficiency conditions (which can manifest in a variety of ways) along with prophylaxis for disastrous exposure to ionizing radiation, but generally speaking, how much is enough? A very nice study on a chronically iodine-deficient population was recently published in the journal Endokrynologia Polska (Polish Journal of Endocrinology):

“Until 1997, Poland was one of the European countries suffering from mild/moderate iodine deficiency. In 1997, a national iodine prophylaxis programme was implemented based on mandatory iodisation of household salt with 30 ± 10 mg KI/kg salt, obligatory iodisation of neonatal formula with 10 μg KI/100 mL and voluntary supplementation of pregnant and breast-feeding women with additional 100-150 μg of iodine. Our aim in this study was to evaluate the iodine status of pregnant women ten years after iodine prophylaxis was introduced.

They examined 100 healthy pregnant women between the fifth and the 38th week of pregnancy for serum TSH, fT(4), fT(3), thyroglobulin (TG), anti-peroxidase antibodies (TPO-Ab), anti-thyroglobulin antibodies (TGAb), urinary iodine concentration (UIC) and thyroid volume and structure by ultrasonography. This really was an iodine-deficient population—28% of the subjects had a goiter. What did their data show?

“Median UIC was significantly higher in the group receiving iodine supplements than in the group without iodine supplements…Serum TSH, fT(3) and fT(3)/fT(4) molar ratio increased significantly during pregnancy while fT(4) declined. Median serum TG was normal: 18.3 ng/mL (range 0.4-300.0 ng/mL) and did not differ between trimesters. Neonatal TSH performed on the third day of life as a neonatal screening test for hypothyroidism was normal.”

Thus the authors concluded:

Iodine supplements with 150 μg of iodine should be prescribed for each healthy pregnant [Polish] woman according to the assumptions of Polish iodine prophylaxis programme to obtain adequate iodine supply.”

Here is a point worth noting for those who are aware of a recent trend for prescribing extremely high doses of supplemental iodine, as high as 50 mg per day and sometimes more: 50 mg = 50,000 μg (micrograms). That’s 333 times the amount recommended by the Polish study. This is not to say that there are never cases where megadoses of iodine may be indicated, but clinicians should maintain a biological perspective and exercise caution.

Regarding tools to support the practitioner’s thoughtful efforts to structure a careful approach to thyroid case management and iodine supplementation, can we rely on urinary iodine concentration (UIC) as a metric? A study published in Clinical Endocrinology suggests that we can’t. The authors set out to…

“…measure breast milk iodine (MI) and urinary iodine (UI) concentrations in healthy newborns and their nursing mothers from an iodine-sufficient region to determine adequacy and to relate these parameters to thyroid function tests in mothers and infants.”

Their study cohort included 48 healthy neonates of 37 to 42 weeks’ gestation and their mothers. Serum thyroid function tests and urinary iodine excretion were measured for infants and mothers, and maternal milk iodine concentration were measured. What did their data show?

Neonatal and maternal UI did not correlate with serum thyroid function tests…Among euthyroid neonates, UI was adequate despite low median maternal UI and MI concentrations. There were no significant correlations between UI or MI and thyroid function tests in the mothers and infants.

What about in cases where there is documented thyroid dysfunction? Is urinary iodine a correlative marker in this patient population. An interesting study published in the journal Endocrine implies that it is not. The authors state:

“The prevalence of thyroid dysfunction varies in different populations. The aim of this cross-sectional study was to analyze the prevalence of undiagnosed thyroid dysfunction and thyroid antibodies and their relationship with urine iodine excretion in a representative sample of 1,124 (55.5% women; mean age: 44.8 ± 15.2 years) non-hospitalized Mediterranean adults, in Catalonia (Spain).”

They measured free thyroxine (fT4), thyroid-stimulating hormone (TSH), thyroperoxidase and thyroglobulin antibodies, and urine iodine. Interestingly, they found thyroid dysfunction in 8.9% of their subjects with 5.3% previously undiagnosed (13.61% and 9.8% in those over age 60). Rough indicators of autoimmune thyroiditis were present: thyroperoxidase antibodies in 2.4% of men and 9.4% of women and thyroglobulin antibodies in 1.3% of men and 3.8% of women. What about the correlation with urine iodine?

No differences were observed in urine iodine between groups with thyroid dysfunction and euthyroidism, or between subjects with positive or negative antibodies.

In other words, urine iodine completely failed to discriminate between those with normal and abnormal thyroid function.

Here’s what the evidence boils down to: iodine supplementation has its place when used with sound clinical judgment and a biological perspective in the hands of a practitioner with the knowledge and experience to assess the need and tolerance of each individual patient with care. As for protection from harmful doses of ionizing radiation, clinicians who employ a functional medicine perspective are well equipped to evaluate your resources for ameliorating oxidative and mutagenic stresses.

 

 

Antibiotic use can promote inflammatory bowel disease in childhood

The use of antibiotics demands great care and discrimination. A paper just published in Gut, An International Journal of Gastroenterology & Hepatology offers further evidence that disruption of the microbial ecology can promote autoimmune disorders. The authors state:

“The composition of the intestinal microflora has been proposed as an important factor in the development of inflammatory bowel diseases (IBD). Antibiotics have the potential to alter the composition of the intestinal microflora. A study was undertaken to evaluate the potential association between use of antibiotics and IBD in childhood.”

They examined all Danish singleton children born from 1995 to 2003 (577,627 children) for correlations between antibiotic prescriptions and IBD while taking into consideration potential confounding variables. They then calculated rate ratios (RRs) of IBD according to antibiotic use. Their data painted a compelling picture:

“IBD was diagnosed in 117 children during 3,173,117 person-years of follow-up. The RR of IBD was 1.84 for antibiotic users compared with non-users. This association appeared to be an effect on Crohn’s disease (CD) alone (RR 3.41) and was strongest in the first 3 months following use (RR 4.43) and among children with ≥7 courses of antibiotics (RR 7.32).”

In other words, there was an 84% increase in IBD for antibiotic users versus non-users. The increase in Crohn’s disease was particularly dramatic—341% in general, 443% in the first 3 months after antibiotic use, and a whopping 732% for children who had seven or more courses of antibiotics. The authors conclude:

Antibiotic use is common in childhood and its potential as an environmental risk factor for IBD warrants scrutiny. This is the first prospective study to show a strong association between antibiotic use and CD in childhood.”

While, as the authors concede, an observational study does not establish causality, prudence dictates that care be taken in evaluating each patient for propensities to autoimmune disorders, and to apply appropriate pro- and prebiotic support during and after antimicrobial therapy.

Vitamin D is an independent risk factor for multiple sclerosis

Yet more evidence for the importance of immune regulation by vitamin D is presented in a paper just published in the journal Neurology. This study investigates the association between vitamin D and central nervous system (CNS) demyelination, the pathological process by which the fatty conductive nerve ‘insulation’ is damaged in disorders like multiple sclerosis. The authors set out to…

“…examine whether past and recent sun exposure and vitamin D status (serum 25-hydroxyvitamin D [25(OH)D] levels) are associated with risk of first demyelinating events (FDEs) and to evaluate the contribution of these factors to the latitudinal gradient in FDE incidence in Australia.”

Over a period of three years they compared 216 subjects aged 18–59 years with a FDE to 395 controls matched for age, sex, and study region who had no CNS demyelination. Besides self-reported sun exposure by life stage the gathered objective measures of skin type and sun related damage, along with vitamin D status. Not surprisingly…

Higher levels of past, recent, and accumulated leisure-time sun exposure were each associated with reduced risk of FDE… Higher actinic skin damage and higher serum vitamin D status were independently associated with decreased FDE risk. Differences in leisure-time sun exposure, serum 25(OH)D level, and skin type additively accounted for a 32.4% increase in FDE incidence from the low to high latitude regions.”

There was a 93% decrease in first demyelinating events for every 10 nmol/L increase in serum 25(OH)D). The authors conclude:

Sun exposure and vitamin D status may have independent roles in the risk of CNS demyelination. Both will need to be evaluated in clinical trials for multiple sclerosis prevention.”

The autoimmune aspect of preterm labor

A paper just published in PLoS ONE (Public Library of Science) presents findings that expand our understanding of the inflammatory aspect of preterm labor.  The authors state:

Preterm parturition is characterized by innate immune activation and increased proinflammatory cytokine levels. This well established association leads us to hypothesize that preterm delivery is also associated with neonatal T lymphocyte activation and maturation.”

For our lay readership, innate immune activation refers to the cell-mediated ‘first phase’ Th1 immune response versus the ‘second phase’ Th2 antibody aspect mediated by T lymphocyte activation. The authors obtained cord blood samples following normal and preterm deliveries, and deliveries complicated by clinical chorioamnionitis (inflammation of the fetal membranes). What did they find?

Infants born following preterm delivery demonstrated enhanced CD4+ T lymphocyte activation… Neonates delivered following clinical chorioamnionitis also demonstrated increased T cell activation. Preterm neonates had an increased frequency of CD45RO+ T cells.”

Autoimmune cross-reactions to environmental stimuli fuels a wide range of disorders. Consider the role of gluten sensitivity in a variety of female reproductive disorders. The authors conclude:

“Preterm parturition is associated with neonatal CD4+ T cell activation, and an increased frequency of CD45RO+ T cells. These findings support the concept that activation of the fetal adaptive immune system in utero is closely associated with preterm labor.

The obvious practical implication is that screening for preterm labor can be accomplished by testing for antibodies to the fetal membranes. In positive cases rational therapy can be applied on a functional basis to address the underlying causes of immune overactivation.

The autoimmune aspect of hair loss

A fascinating study was just published in Medicinski arhiv (Medical Archives, Journal of the Academy of Medical Sciences of Bosnia and Herzegovina) that illuminates the type of autoimmune dysfunction involved in alopecia areata, a common cause of hair loss. The authors state:

Alopecia areata (AA) is a heterogeneous disease characterized by nonscarring hair loss on the scalp or other parts of the body. A wide range of clinical presentations can occur-from a single patch of hair loss (alopecia unilocularis, AUl), multiple patches (alopecia multilocularis, AM) to complete loss of hair on the scalp (alopecia totalis, AT) or the entire body (alopecia universalis, AU). The cause of AA is unknown although most evidence supports the hypothesis that AA is a T-cell mediated autoimmune disease of the hair follicle and that cytokines play an important role.”

The authors set out to evaluate serum concentrations of interferon-gamma (IFN-g, a major proinflammatory cytokine) in 60 patients with AA in comparison to 20 healthy subjects. They also investigated for an association between IFN-g and the clinical type of AA and duration of the disease. What did their data show?

“The serum concentration of IFN-g in patients with AA was significantly higher than that in the control group. Significantly elevated serum IFN-g were noticed in patients with AU type, especially those suffering from AT, compared with both patients with AUI and patients with AM clinical type. There was no significant difference in serum IFN-g concentration between patients with AUI and AM group, as well as between patients with AT and AU. No correlations were found between duration of disease and the serum levels of IFN-g.”

This clearly shows the autoimmune basis of hair loss in general and the role of IFN-g in particular. Autoimmune conditions require a functional approach that uses up-to-date methods to objectively define the underlying causal factors such as IFN-g for treatments that are targeted, physiological and rational. The authors conclude:

Our findings confirm previously published data that the Th1 type cytokine IFN-g is elevated in the serum of AA patients.

Therapeutic resources for inflammatory bowel disease

Autoimmune disease in general and inflammatory bowel disease in particular arise from a constellation of causes that should be investigated and addressed on an individual basis. Nonetheless, methods that calm the inflammatory cascade (without harmful side-effects) are important practical tools. As forthcoming posts will describe in greater detail, nitric oxide production is a critical step in the production of damaging inflammation. A paper published in the European Journal of Clinical Investigation highlights this fact:

Nitric oxide (NO) production, as detectable by indirect and direct methods, as well as the expression of inducible nitric oxide synthase (iNOS) in the intestinal mucosa appear to be enhanced in active ulcerative colitis and, when in excess, to play a proinflammatory role in the disease. Despite some conflicting data, there is evidence that NO production is also increased in Crohn’s disease. Many inflammatory features of inflammatory bowel disease are in keeping with the physiological properties of NO…”

And of interest for clinical case managment…

“The drugs currently used in the treatment of inflammatory bowel disease (steroids, salicylates) do not seem to exert substantial effects on intestinal NO synthesis.”

A study published in the British Journal of Pharmacology examines the ability of the natural flavonoid quercitrin (related to quercitin) to inhibit production of iNOS (‘inducible nitric oxide synthase, the ‘bad’ nitric oxide producing enzyme). The authors state:

Quercitrin, 3-rhamnosylquercetin, is a bioflavonoid with antioxidant properties, which exerts anti-inflammatory activity in experimental colitis. In the present study, different in vivo experiments were performed in order to evaluate the mechanisms of action involved in this effect, with special attention to its effects on proinflammatory mediators, including nitric oxide (NO).”

They examined the effects of quercitrin on inflammation of the intestinal mucosa (‘lining’) induced by DSS (dextran sodium sulfate) both preventatively and, in another cohort, on already established colitis. The results were significant:

“Oral treatment of quercitrin…ameliorated the evolution of the inflammatory process induced when administered in a preventative dosing protocol…on established colitis, it facilitated the recovery of the inflamed mucosa…The beneficial effects exerted by quercitrin were evidenced both histologically and biochemically, and were associated with an improvement in the colonic oxidative status…”

Regarding the role of NO and inflammatory bowel disease…

“…a reduction of colonic NO synthase activity was observed, probably related to a decreased expression in the inducible form of the enzyme [iNOS] via downregulation in the colonic activity of the nuclear factor-κB.”

The authors discuss their findings in summary:

“During the last decade, it has become increasingly clear that NO overproduction by iNOS is deleterious to intestinal function…thus contributing significantly to gastrointestinal immunopathology…the results obtained in the present study reveal that colonic inflammation is associated with a higher colonic NOS activity, mainly attributed to an increase in iNOS expression…the effect showed by quercitrin is most probably related to an inhibition of the expression of this enzyme, which is upregulated as a consequence of the colonic inflammatory process…The antioxidant and/or scavenging properties ascribed to this flavonoid could also contribute to its intestinal anti-inflammatory effect…”

A study published in the European Journal of Immunology sheds more light on the use of quercitin for inflammatory bowel disease. Examining the relationship between quercitrin and quercitin, the authors find…

“…that the in vivo effects of quercitrin…can be mediated by the release of quercetin generated after glycoside’s cleavage by the intestinal microbiota. This is supported by the fact that quercetin, but not quercitrin, is able to down-regulate the inflammatory response of bone marrow-derived macrophages in vitro.”

They also describe evidence for the effect of quercitin on iNOS and the the NF-κB pathway:

“Moreover, we have demonstrated that quercetin inhibits cytokine and inducible nitric oxide synthase expression through inhibition of the NF-κB pathway…(both in vitro and in vivo). As a conclusion, our report suggests that quercitrin releases quercetin in order to perform its anti-inflammatory effect…”

A paper published in the journal Digestive Diseases examines the ability of quercitin to help repair the gut barrier in inflammatory bowel disease. Regarding the intestinal epithelial barrier (‘lining’) the authors state:

In inflammatory bowel disease (IBD), epithelial barrier function is impaired contributing to diarrhea by a leak flux mechanism and perpetuating inflammation by an increased luminal antigen uptake. This barrier of the intestinal epithelium is composed of the apical enterocyte membrane and the epithelial tight junction (TJ) and can be affected by TJ alterations, induction of epithelial apoptoses and appearance of gross lesions like erosions or ulcers as well as by accelerated transcytotic antigen uptake.”

They note that in addition to therapies that oppose Th1 cytokine activity in Crohn’s disease  and Th2 cytokine activity in ulcerative colitis, other agents have been shown to improve barrier function:

“…zinc has been shown to improve barrier function in CD, although the inherent mechanisms are unknown. Finally, food components can strengthen the epithelial barrier as for example the flavonoid quercetin which has been shown to upregulate claudin-4 within the epithelial TJ.”

Curcumin (extracted from the yellow spice turmeric) should also be considered in the functional management of inflammatory bowel disease. The authors of a study published in the journal Inflammatory Bowel Diseases observe:

“Neutrophils (PMN) are the first cells recruited at the site of inflammation. They play a key role in the innate immune response by recognizing, ingesting, and eliminating pathogens and participate in the orientation of the adaptive immune responses. However, in inflammatory bowel disease (IBD) transepithelial neutrophil migration leads to an impaired epithelial barrier function, perpetuation of inflammation, and tissue destruction via oxidative and proteolytic damage. Curcumin (diferulolylmethane) displays a protective role in mouse models of IBD and in human ulcerative colitis, a phenomenon consistently accompanied by a reduced mucosal neutrophil infiltration.”

They investigated the phenomenon of neutrophil modulation by curcumin in vitro and in vivo. Their accumulated data demonstrated that…

“Curcumin attenuated lipopolysaccharide (LPS)-stimulated expression and secretion of macrophage inflammatory protein (MIP)-2, interleukin (IL)-1β, keratinocyte chemoattractant (KC), and MIP-1α in colonic epithelial cells (CECs) and in macrophages. Curcumin significantly inhibited PMN chemotaxis against MIP-2, KC, or against conditioned media from LPS-treated macrophages or CEC, a well as the IL-8-mediated chemotaxis of human neutrophils. At nontoxic concentrations, curcumin inhibited random neutrophil migration, suggesting a direct effect on neutrophil chemokinesis.”

In other words, curcumin was shown to significantly attenuate proinflammatory cytokine expression and white blood cell ‘attack movements’. Thus the authors conclude:

“Our results indicate that curcumin interferes with colonic inflammation partly through inhibition of the chemokine expression and through direct inhibition of neutrophil chemotaxis and chemokinesis.”

A double-blind, placebo-controlled trial of curcumin for the treatment of ulcerative colitis was reported in the journal Clinical Gastroenterology and Hepatology. The authors state:

“Curcumin is a biologically active phytochemical substance present in turmeric and has pharmacologic actions that might benefit patients with ulcerative colitis (UC). The aim in this trial was to assess the efficacy of curcumin as maintenance therapy in patients with quiescent ulcerative colitis (UC).”

They divided a cohort of 89 patients with quiescent UC into a treatment group of 45 who added 1 gram of curcumin taken two times per day to their usual therapy. The other 44 got a placebo.  After 6 months the relapse percentages were 4.65% for those who received curcumin and 20.51% for the placebo group.

“Furthermore, curcumin improved both CAI [clinical activity index] and EI [endoscopic index], thus suppressing the morbidity associated with UC.”

The authors conclude:

Curcumin seems to be a promising and safe medication for maintaining remission in patients with quiescent UC. Further studies on curcumin should strengthen our findings.”

It’s also worth noting a paper published in the journal Current Pharmaceutical Design examines the multiple anti-inflammatory effects of curcumin. The authors first state:

Inflammatory bowel disease (IBD) is a chronic relapsing-remitting condition that afflicts millions of people throughout the world and impairs their daily functions and quality of life… it appears to be driven by inflammatory cytokines such as tumor necrosis factor (TNF)-α. Hence, there is a strong interest in agents that can block the generation or actions of inflammatory cytokines.”

They note that earlier research has demonstrated that curcumin inhibits inflammation through action on cyclooxygenases 1, 2 (COX-1, COX-2), lipoxygenase (LOX), TNF-α, interferon γ (IFN-γ), inducible nitric oxide synthase (iNOS), and the transcriptional nuclear factor kappa B (NF-κB, a key factor in the production of proinflammatory cytokines), and has a strong anti-oxidant effect.

“Therefore, in recent years, the efficacy of curcumin has been investigated in several experimental models of IBD. The results indicate striking suppression of induced IBD colitis and changes in cytokine profiles…”

And in an early successful human IBD study..

“…patients were given curcumin (360mg/dose) 3 or 4 times/day for three months. Further, curcumin significantly reduced clinical relapse in patients with quiescent IBD.”

While it’s difficult to predict ahead of time which patients will have the best response to agents such as curcumin and quercitin, since they are so safe and wholesome we can welcome the authors’ conclusion:

The inhibitory effects of curcumin on major inflammatory mechanisms like COX-2, LOX, TNF-α, IFN-γ, NF-κB and its unrivaled safety profile suggest that it has bright prospects in the treatment of IBD.”